Anti-CD2 monoclonal antibody 12-15

Drug Profile

Anti-CD2 monoclonal antibody 12-15

Latest Information Update: 26 Aug 2002

Price : $50

At a glance

  • Originator Medical University of South Carolina
  • Class Monoclonal antibodies
  • Mechanism of Action CD2 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Heart transplant rejection

Most Recent Events

  • 14 Jul 1998 No-Development-Reported for Heart transplant rejection in USA (Unknown route)
  • 15 Dec 1995 New profile
  • 14 Dec 1995 Preclinical development for Heart transplant rejection in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top